Tags : PRIMA

GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study

Tuba Khan July 15, 2019

Shots: The P-III PRIMA study involves assessing of Zejula (200 mg, qd) vs PBO as 1L maintenance therapy in patients in a ratio (2:1) with stage III or IV ovarian […]readmore

Tags : PRIMA

GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : PRIMA

﻿GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study